I do not know the impact that Trump and hos healthcare comments will have on CSL. It would appear that he was saying that price rises for drugs may not be the right thing to do.
If you look at the CSL announcement, it used words like "strong sales performance" "quickly to fulfill demand". This suggests to me that the increase in profit is driven by volume and market share increase not price. So when Trump is having a go at big pharma, CSL would appear to not be the company under attack. (It may get caught in a sector movement, but irrational share pricing is what provides opportunities to investors.)
HT1
Ann: FY2017 Profit Upgrade, page-70
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$307.13 |
Change
-0.770(0.25%) |
Mkt cap ! $148.2B | |||
| Open | High | Low | Value | Volume |
| $307.51 | $308.38 | $306.26 | $47.51M | 154.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16 | $307.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $307.15 | 10 | 3 |
View Market Depth
| Last trade - 12.44pm 29/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |